Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Anemia, Refractory, with Excess of Blasts 2Lymphoma, Mantle-Cell 1Hemoglobinuria, Paroxysmal 1Glioblastoma 1Anemia, Aplastic 1

Interventions

Rituximab 93Cyclophosphamide 72fludarabine phosphate 53Whole-Body Irradiation 43Mycophenolic Acid 40Peripheral Blood Stem Cell Transplantation 39Bortezomib 30Tacrolimus 29Etoposide 29Cyclosporine 28Melphalan 26Filgrastim 26Busulfan 26Methotrexate 24Lenalidomide 23Cytarabine 23ibrutinib 20Vincristine 20Granulocyte Colony-Stimulating Factor 20Antilymphocyte Serum 20Doxorubicin 18Bendamustine Hydrochloride 18Dexamethasone 16Sirolimus 14fludarabine 13Carmustine 13Cord Blood Stem Cell Transplantation 12Calcium Dobesilate 12Radiotherapy 11Prednisone 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Mantle-Cell × Basiliximab × Clear all
NCT00594308 2014-10-06

In-Vivo Activated T-Cell Depletion to Prevent GVHD

Indiana University

Phase NA Terminated
10 enrolled 11 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡